Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing awareness along with the high prevalence of the avascular necrosis disease
4.2.2 Rising preference of surgeries to cure osteonecrosis
4.2.3 Rising preference of bone grafting surgical procedures with the less pain substitute procedures
4.2.4 Consolidation of large healthcare providers in the U.S.
4.2.5 Technological advancements in the development of surgical implants
4.3 Restraints
4.3.1 The high cost of surgical procedures and related side effects
4.3.2 Worsening regulatory landscape and growing cost of noncompliance in developed countries
4.4 Opportunities
4.4.1 Growing demand for non-invasive treatments for faster recovery
4.5 Technology Trends & Assessment
4.5.1 Acceptance of synthetic bone-graft over natural ones
4.5.2 Nanotechnology
4.5.3 Rising demand for incorporating recombinant DNA technology in surgical implants
4.5.4 Development of titanium-foam implant for bone grafting
4.5.5 Customized Degradable Implants
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research & Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Epidemiology of Avascular Necrosis
6 Global Avascular Necrosis Market, by Type
6.1 Introduction
6.2 Non-trauma Related Avascular Necrosis
6.2.1 Age Group
6.2.1.1 Third Decade
6.2.1.2 Fifth Decade
6.2.2 Causes
6.2.2.1 Caisson disease
6.2.2.2 Sickle cell anaemia
6.2.2.3 Steroid Abuse
6.2.2.4 Alcohol Abuse
6.3 Trauma-Related Avascular Necrosis
7 Global Avascular Necrosis Market, by Site
7.1 Introduction
7.2 Hip Bone
7.3 Knee
7.4 Shoulder
8 Global Avascular Necrosis Market, by Diagnosis
8.1 Introduction
8.2 Imaging
8.2.1 X-Ray
8.2.2 CT Scan
8.2.3 MRI
8.2.4 PET
8.3 Biopsy
9 Global Avascular Necrosis Market, by Treatment
9.1 Introduction
9.2 Medication
9.2.1 Medication by NSAIDs (Non-Steroidal Anti-inflammatory Drugs)
9.2.2 Medication by Bisphosphonates
9.2.3 Medication by Blood Thinners
9.3 Electrical Stimulation
9.4 Gene Therapy
9.5 Surgery
9.5.1 Core Decompression
9.5.2 Osteotomy
9.5.3 Bone Graft
9.5.4 Arthoplasty
10 Global Avascular Necrosis Market, by End-User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Diagnostic Centers
10.4 Ambulatory Surgical Centers
11 Global Avascular Necrosis Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1.1 The Middle East
11.5.1.2 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Market Share Analysis
12.2.1 Introduction
12.3 Key Developments
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer Healthcare AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Boehringer Ingelheim GmbH
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Pfizer Inc.
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Merck KGaA
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Stryker Corporation
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Medtronic PLC
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Aurobindo Pharma
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Integra LifeSciences Corporation
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Zimmer Biomet Holdings
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Wright Medical Group N.V.
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
13.12 Grifols SA
13.12.1 Company Overview
13.12.2 Financial Overview
13.12.3 Products Offering
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.12.6 Key Strategy
13.13 Smith & Nephew
13.13.1 Company Overview
13.13.2 Financial Overview
13.13.3 Products Offering
13.13.4 Key Developments
13.13.5 SWOT Analysis
13.13.6 Key Strategy
13.14 Ethicon Inc.
13.14.1 Company Overview
13.14.2 Financial Overview
13.14.3 Products Offering
13.14.4 Key Developments
13.14.5 SWOT Analysis
13.14.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO's Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print